Bintrafusp alfa enhances the antitumor efficacy of anti-VEGF and VEGF receptor kinase inhibitors in preclinical solid tumor models.

被引：0
|
作者：
Yeung, Tsz-Lun [1 ]
Lazorchak, Adam [1 ]
Yu, Huakui [1 ]
Qi, Jin [1 ]
Qin, Guozhong [1 ]
Marelli, Bo [1 ]
Fu, Kai [1 ]
Lan, Yan [1 ]
机构：
[1] Serono Res & Dev Inst Inc, Billerica, MA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
443
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Novel, orally active multi-kinase inhibitors of c-MET and the VEGF receptor family exhibit potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Beaulieu, N
    Nguyen, H
    Beaulieu, C
    Dupont, I
    Barsalou, A
    Gravel, S
    Chute, I
    Robert, MF
    Lefebvre, S
    Dubay, M
    Rahil, J
    Claridge, S
    Raeppel, F
    Saavedra, O
    Bernstein, N
    Granger, MC
    Zhan, LJ
    Llewellyn, D
    Wal, A
    Deziel, R
    Besterman, J
    Wang, J
    Vaisburg, A
    MacLeod, AR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9029S - 9030S
  • [2] Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors
    Schlaeppi, JM
    Wood, JM
    CANCER AND METASTASIS REVIEWS, 1999, 18 (04) : 473 - 481
  • [3] Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors
    Jean-Marc Schlaeppi
    Jeanette M. Wood
    Cancer and Metastasis Reviews, 1999, 18 : 473 - 481
  • [4] Anti-VEGF enhances the antitumor effect of CD40
    Selvaraj, Sathishkumar
    Raundhal, Mahesh
    Patidar, Ashok
    Saha, Bhaskar
    INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (08) : 1983 - 1988
  • [5] Anti-IL-17RA enhances the efficacy of anti-VEGF
    Taylor, Brooklyn E.
    Barber, Katherine
    Lee, Chieh
    Howell, Scott J.
    Taylor, Patricia R.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [6] Interaction of VEGF and Notch pathways in tumor angiogenesis: DLL4 contributes to tumor resistance to anti-VEGF therapy in preclinical models
    Li, Ji-Liang
    Sainson, Richard
    Oon, Chern
    Leek, Russell
    Turley, Helen
    Harrington, Laura
    Sheldon, Helen
    Bernhard, Eric
    Im, Jae
    Shi, Wen
    Harris, Adrian
    CANCER RESEARCH, 2009, 69
  • [7] MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models
    Mark, M.
    Zhang, Y.
    Su, Y.
    Romero, M. S.
    Severin, C.
    Zheng, Z.
    Mendoza, N.
    Kaufman, D. W.
    Woude, G. F. Vance
    Filvaroff, E.
    EJC SUPPLEMENTS, 2008, 6 (12): : 175 - 175
  • [8] Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept
    Hong, Hye Kyoung
    Park, Young Joo
    Kim, Duk Ki
    Ryoo, Na-Kyung
    Ko, You-Jin
    Park, Kyu Hyung
    Kim, Ho Min
    Woo, Se Joon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (13)
  • [9] An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody
    Shen, Juqun
    Vil, Marie D.
    Zhang, Haifan
    Tonra, James R.
    Rong, Ling L.
    Damoci, Chris
    Prewett, Marie
    Deevi, Dhanvanthri S.
    Kearney, Jessica
    Surguladze, David
    Jimenez, Xenia
    Iacolina, Michelle
    Bassi, Rajiv
    Zhou, Kai
    Balderes, Paul
    Mangalampalli, Venkat R. M.
    Loizos, Nick
    Ludwig, Dale L.
    Zhu, Zhenping
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 357 (04) : 1142 - 1147
  • [10] Antitumor activity of lenvatinib against acquired resistance tumor to anti-VEGF therapy in mouse syngeneic tumor models
    Ichikawa, Kenji
    Miyano, Saori Watanabe
    Minoshima, Yukinori
    Matsui, Junji
    Funahashi, Yasuhiro
    CANCER RESEARCH, 2019, 79 (13)
12345